ARTEMIS-UC, APOLLO-CD topline results: PRA023 safe, effective in Crohn’s disease, UC

Topline findings from the phase 2 ARTEMIS-UC and phase 2a APOLLO-CD trials showed that PRA023, an anti-TL1A monoclonal antibody, was safe and effective for Crohn’s disease and ulcerative colitis, Prometheus Biosciences announced.“We are beyond enthusiastic with these study results and what they could mean for patients suffering from IBD,” Mark McKenna, chairman and CEO of Prometheus Biosciences, said in the release. “The performance of PRA023 in both UC and Crohn’s patients has surpassed our expectations. We believe PRA023 and our precision medicine approach hasRead More

Generated by Feedzy